Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NUVL

NUVL - Nuvalent, Inc. Stock Price, Fair Value and News

$84.22-0.42 (-0.50%)
Delayed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

NUVL Price Action

Last 7 days

-3.0%

Last 30 days

-7.6%

Last 90 days

-22.0%

Trailing 12 Months

19.4%

NUVL RSI Chart

NUVL Valuation

Market Cap

5.5B

Price/Earnings (Trailing)

-24.66

Price/Sales (Trailing)

428.9

EV/EBITDA

-23.57

Price/Free Cashflow

-36.09

NUVL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NUVL Fundamentals

NUVL Revenue

Revenue (TTM)

14.0M

NUVL Earnings

Earnings (TTM)

-224.3M

Earnings Growth (Yr)

-150.69%

Earnings Growth (Qtr)

-47.54%

NUVL Profitability

EBT Margin

-1569.32%

Return on Equity

-20%

Return on Assets

-18.86%

Free Cashflow Yield

-2.77%

NUVL Investor Care

Shares Dilution (1Y)

15.45%

Diluted EPS (TTM)

-3.47

NUVL Alerts

  • 4 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202309.1M14.0M0
202201.5M2.9M4.3M
2021000114.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Nuvalent, Inc.

NUVL
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEnuvalent.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES78

Nuvalent, Inc. Frequently Asked Questions

What is the ticker symbol for Nuvalent, Inc.? What does NUVL stand for in stocks?

NUVL is the stock ticker symbol of Nuvalent, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nuvalent, Inc. (NUVL)?

As of Fri Dec 20 2024, market cap of Nuvalent, Inc. is 5.53 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NUVL stock?

You can check NUVL's fair value in chart for subscribers.

Is Nuvalent, Inc. a good stock to buy?

The fair value guage provides a quick view whether NUVL is over valued or under valued. Whether Nuvalent, Inc. is cheap or expensive depends on the assumptions which impact Nuvalent, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NUVL.

What is Nuvalent, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, NUVL's PE ratio (Price to Earnings) is -24.66 and Price to Sales (PS) ratio is 428.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NUVL PE ratio will change depending on the future growth rate expectations of investors.